Results 231 to 240 of about 52,424 (257)
Some of the next articles are maybe not open access.
Enriching the antibiotic armamentarium for acute bacterial skin and skin structure infections
The Lancet Infectious Diseases, 2019no abstract available ...
Bassetti M., Righi E.
openaire +4 more sources
Current Opinion in Infectious Diseases, 2018
Purpose of review To summarize the current finding on SSTIs/ABSSSIs treatment duration. Recent findings In 2013, the FDA approved the definition of acute bacterial skin and skin structure infections (ABSSSIs).
Corcione, Silvia +1 more
openaire +2 more sources
Purpose of review To summarize the current finding on SSTIs/ABSSSIs treatment duration. Recent findings In 2013, the FDA approved the definition of acute bacterial skin and skin structure infections (ABSSSIs).
Corcione, Silvia +1 more
openaire +2 more sources
Drugs of Today, 2018
Delafloxacin meglumine (Baxdela, WQ-3034, ABT-492, RX-3341; Melinta Therapeutics) was approved by the U.S. Food and Drug Administration (FDA) in June 2017 for the treatment of acute bacterial skin and skin structure infections on the basis of data from two phase III trials.
G, Kaul +3 more
openaire +2 more sources
Delafloxacin meglumine (Baxdela, WQ-3034, ABT-492, RX-3341; Melinta Therapeutics) was approved by the U.S. Food and Drug Administration (FDA) in June 2017 for the treatment of acute bacterial skin and skin structure infections on the basis of data from two phase III trials.
G, Kaul +3 more
openaire +2 more sources
Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections
Drugs, 2015Intravenous dalbavancin (Dalvance™; Xydalba™) is approved for use in adult patients with acute bacterial skin and skin structure infections (ABSSSI), with the recommended regimen being a 1000 mg dose followed 1 week later by a 500 mg dose. In the multinational DISCOVER 1 and 2 trials in adult patients with ABSSSI, dalbavancin treatment was noninferior ...
openaire +2 more sources
Expert Opinion on Pharmacotherapy, 2012
Bacterial resistance is increasing on a global basis, making treatment options more limited. The development of new agents to meet this threat is a matter of urgency. Ceftaroline fosamil , a member of an advanced cephalosporin class of antimicrobials, is currently approved by the US Food and Drug Administration for use in for acute bacterial skin and ...
Anthony M, Casapao +3 more
openaire +2 more sources
Bacterial resistance is increasing on a global basis, making treatment options more limited. The development of new agents to meet this threat is a matter of urgency. Ceftaroline fosamil , a member of an advanced cephalosporin class of antimicrobials, is currently approved by the US Food and Drug Administration for use in for acute bacterial skin and ...
Anthony M, Casapao +3 more
openaire +2 more sources
Expert Review of Clinical Pharmacology, 2016
Acute bacterial skin and skin structure infections (ABSSSI) have evolved over a relatively short period of time to become one of the most challenging medical problems encountered in clinical practice. Notably the high incidence of methicillin-resistant S.
Jaime E, Verastegui +2 more
openaire +2 more sources
Acute bacterial skin and skin structure infections (ABSSSI) have evolved over a relatively short period of time to become one of the most challenging medical problems encountered in clinical practice. Notably the high incidence of methicillin-resistant S.
Jaime E, Verastegui +2 more
openaire +2 more sources
American Journal of Health-System Pharmacy, 2014
The impact of an antimicrobial stewardship program (ASP) on the management of therapy and hospital resources for patients with acute bacterial skin and skin structure infections (ABSSSIs) at a community teaching hospital was evaluated.A retrospective, observational chart review was performed to evaluate the impact of the ASP on patients admitted to ...
Timothy R, Pasquale +8 more
openaire +2 more sources
The impact of an antimicrobial stewardship program (ASP) on the management of therapy and hospital resources for patients with acute bacterial skin and skin structure infections (ABSSSIs) at a community teaching hospital was evaluated.A retrospective, observational chart review was performed to evaluate the impact of the ASP on patients admitted to ...
Timothy R, Pasquale +8 more
openaire +2 more sources
Single-Dose Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections
Drugs, 2016Intravenous dalbavancin (Dalvance®, Xydalba®), first approved as a two-dose regimen for the treatment of acute bacterial skin and skin structure infections (ABSSSI), has now been additionally approved as a single-dose regimen. This narrative review discusses the pharmacological properties of intravenous dalbavancin and its clinical efficacy and ...
openaire +2 more sources
Postgraduate Medicine, 2014
Ceftaroline fosamil is a broad-spectrum antibiotic approved by the US Food and Drug Administration (FDA) for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and community-acquired bacterial pneumonia. The Clinical Assessment Program and Teflaro Utilization Registry (CAPTURE) is a multicenter registry study of patients ...
John D, Evans +3 more
openaire +2 more sources
Ceftaroline fosamil is a broad-spectrum antibiotic approved by the US Food and Drug Administration (FDA) for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and community-acquired bacterial pneumonia. The Clinical Assessment Program and Teflaro Utilization Registry (CAPTURE) is a multicenter registry study of patients ...
John D, Evans +3 more
openaire +2 more sources
New antibiotics in the management of acute bacterial skin and skin structure infections.
Skin therapy letter, 2016Acute bacterial skin and skin-structure infections (ABSSSIs), often caused by aerobic gram-positive cocci, are most often mild-tomoderate infections that can easily be treated in an outpatient setting. With the rates of these infections substantially increasing in the past decade, owing in part to the emergence of community acquired methicillin ...
K, Gleghorn, E, Grimshaw, E K, Kelly
openaire +1 more source